Hugin-News: SINCLAIR PHARMA PLC.

Sinclair Pharma plc meldet Dr. Reddy's Laboratories Inc. als neuen Vermarktungspartner für Sebclair in den USA

27 September 2007, Godalming, GB: Sinclair Pharma plc ("Sinclair",
SPH:L), das Spezialpharmaunternehmen, meldet, dass es die
Exklusivrechte in den USA für sein Produkt gegen seborrhoische
Dermatitis, Sebclair, in Konzession an Dr. Reddy's Laboratories
vergeben hat, eine Tochtergesellschaft von Dr. Reddy's Laboratories
Limited (NYSE:RDY). Dr. Reddy's wird das Produkt unter einem neuen
Markennamen über seine neue Dermatologie-Sparte vermarkten.

Im Rahmen der Vereinbarung erhält Dr. Reddy's das Exklusivrecht in
den USA für Sebclair und verwandte Nebenproduktlinien für die
Laufzeit des Patentschutzes von Sebclair. Vereinbarungsgemäß wird
Sinclair über die Vertragsdauer hinweg bestimmte Meilensteinzahlungen
erhalten. Nach der Vermarktung des Produktes wird Sinclair Tantiemen
auf Grundlage des Nettoabsatzes erhalten.

Für Dr. Reddy's steht der Ausbau der Präsenz des Unternehmens im
Bereich Dermatologie in den USA im Brennpunkt, einem Sektor, der nach
Schätzungen $5 Mrd. wert ist[i]. Sebclair wird ein wichtiger
Bestandteil des künftigen Portfolios von Dr. Reddy's für
Dermatologieprodukte sein. Dr. Reddy's erwartet, dass Sebclair
innerhalb eines Jahres durch einen neuen Außendienst eingeführt
werden wird, der sich spezifisch an Dermatologen wendet.

Dr. Michael Flynn, CEO von Sinclair Pharma, meinte: "Dieser
aufregende neue Abschluss heißt, dass Sebclair nun ins kommerzielle
Leben eintritt. Dr. Reddy's verfügt über eine starke Präsenz
weltweit, und wir sind überzeugt, dass Seblair eine Gelegenheit
bietet, die Ambitionen des Unternehmens für den Dermatologiesektor in
den USA zu unterstützen."

Jeffery Wasserstein, geschäftsführender Vizepräsident von Dr. Reddy's
Laboratories, fügte hinzu "Wir freuen uns sehr über die Partnerschaft
mit Sinclair zu unserem Eintritt in den US-Markt für Dermatologie."


- Ende -


Weitere Informationen erhalten Sie von:

Sinclair Pharma plc Tel: +44
(0) 1483 410 600
Dr Michael Flynn, CEO
Zoe McDougall, Director of Communications

Capital MS&L
Mary Clark, Halina Kukula Tel +44
(0)20 7307 5340


Notes to Editors:

About Seborrheic Dermatitis and Sebclair TM
Seborrheic dermatitis is a common skin condition that affects areas
of the body with a particularly high concentration of sebaceous
glands. This may include the eyebrows, bridge of the nose,
naso-labial folds, ears and chest. It manifests as erythema
(reddening), which progresses to flakiness and at its most severe,
crusting of the skin. Seborrheic dermatitis of the scalp is also
particularly common, and in its mildest form may be referred to as
dandruff.

Seborrheic dermatitis is a common condition characterized by flaky,
red skin. It is most common in men and may be present in 5% of the
adult population[ii]. In 2006, there were over 1.5 million visits to
physicians for seborrheic dermatitis (IMS-NDTI). It is estimated
that patients spend over $110 million on prescription products to
treat this condition and there is a significant amount spent on
Over-the-Counter medications as well.iii

Sebclair(TM) cream is registered in the US and EU and addresses the
skin market. Sebclair shampoo, recently registered in the EU,
addresses the scalp sector of the market.

Seborrheic dermatitis also often appears as cradle cap in infants of
around six months. It usually clears by 18 months but can be a
persistent problem during this time. After infancy, the condition is
most common in middle age or older people. It may also be associated
with a poor diet and obesity, HIV and neurological conditions such as
Parkinson's disease.

At present there are various approaches to the management of
seborrheic dermatitis but there is no 'gold-standard' product. Many
of the treatments focus on the potential presence of fungi or other
organisms on the surface of the skin, and topical corticosteroids are
also frequently employed[iii]. Although topical corticosteroids are
commonly used, they are also disliked, as these drugs may cause
atrophy of the skin and are usually restricted to short treatment
periods, particularly on facial skin[iv]. Emollients, lithium-based
and salicylic acid-based creams are considered to improve the
condition.

Other seborrheic dermatitis treatments
Seborrheic dermatitis is frequently treated with topical
corticosteroids. However, this group of drugs may have unfavourable
side effects, especially when used long-term or on sensitive areas of
skin such as the face, hands, or on children. These effects vary
from mild and reversible thinning, to irreversible telangiectasiae
(fine blood vessels becoming visible at the surface of the skin) and
striae distensae (marks similar in appearance to 'stretch marks').
Steroids' effectiveness may also become less effective with continued
use, which may lead to the escalation to a more potent steroid[v].
There may also be a risk of growth suppression and adrenal
suppression in children with the use of topical steroids[vi].
SebclairTM does not contain corticosteroids.

There are also other therapeutic agents that may be used in SD; these
include topical antifungal agents, sulfur-sulfacetamide combinations,
sulfacetamide, zinc pyrithione and selenium sulfide.

About Sinclair Pharma plc www.sinclairpharma.com
Sinclair Pharma plc is an international specialty pharmaceutical
company. It has a growing sales and marketing operation that is
already present in France, Italy, the UK, Spain and Portugal, and a
complementary marketing partner network that spans 82 countries.
Sinclair has proven expertise in acquiring or developing commercially
attractive and undervalued products, registering these products and
bringing them to market within a short time frame. The company
focuses on niche therapeutic areas and its current portfolio includes
products for dermatological conditions and oral health.

"Safe Harbor" Statement under the US Private Securities Litigation
Reform Act of 1995: Some or all of the statements in this document
that relate to future plans, expectations, events, performances and
the like are forward-looking statements, as defined in the US Private
Securities Litigation Reform Act of 1995. Actual results of events
could differ materially from those described in the forward- looking
statements due to a variety of factors.

[i] 2005 : Dermatology market to 2010, Fox Analystics
[ii] Pirkhammer D et al, Brit Journal Dermatology 2000, 143 (5),
964-968
iii The Burden of Skin Diseases 2004; Journal of the American Academy
of Dermatology, September 2006; pp 490-500)
[iii] Tofte SJ, Hanifin JM. Current Management and therapy of atopic
dermatitis. J Am Acad Dermatol 2001; 44 (Suppl): S13-16
[iv] Dreno B, Chosidow O, Revuz J et al. Lithium gluconate 8% vs.
ketonazole 2% in the treatment of seborrheic dermatitis: a
multicentre, randomized study. Br J Dermatol 2003; 148: 1230-1236
[v] Atherton DJ, BMJ. Topical Corticosteroids in atopic
dermatitis. 2003;327:942-943
[vi] Siklar Z, Bostanci I, Atli O, Dallar Y. Pediatr Dermatol. 2004
Sep-Oct;21(5):561-3

Die Pressemitteilung ist auf folgendem Link als PDF abrufbar: